LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000314.8:c.722_723dup
PTEN
· NP_000305.3:p.(Glu242LeufsTer15)
· NM_000314.8
GRCh37: chr10:89717695 C>CTT
·
GRCh38: chr10:87957938 C>CTT
Gene:
PTEN
Transcript:
NM_000314.8
Final call
Likely Pathogenic
PVS1 very strong
PM2 supporting
Variant details
Gene
PTEN
Transcript
NM_000314.8
Protein
NP_000305.3:p.(Glu242LeufsTer15)
gnomAD AF
ClinVar
Pathogenic
OncoKB
Likely Oncogenic
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PVS1 very strong: the p.E242Lfs*15 frameshift is 5' of the PTEN VCEP p.D375 NMD threshold and is predicted to undergo nonsense-mediated decay.
2
PM2 supporting: the variant is absent from gnomAD v2.1 and v4.1, satisfying the PTEN VCEP population-frequency rule.
Final determination:
PTEN Expert Panel Rule20 assigns Likely Pathogenic when one very strong pathogenic criterion and one supporting pathogenic criterion are present; here these are PVS1 very strong and PM2 supporting.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | Met | Met: the p.E242Lfs*15 frameshift is 5' of the PTEN VCEP p.D375 NMD threshold, so the decision tree assigns full-strength PVS1. |
cspec
vcep_pvs1_decisiontree_pten
|
| PS1 | N/A | Not applicable: c.722_723dup is a frameshift, whereas PTEN PS1 requires a pathogenic same-amino-acid or qualifying splice-site comparison. |
cspec
|
| PS2 | Not assessed | Not assessed: no documented proband-level parental testing, confirmed maternity and paternity, or absence of family history for c.722_723dup. |
cspec
|
| PS3 | Not assessed | Not assessed: the governing PTEN assay table covers missense variants and contains no entry for this frameshift, c.722_723dup / p.E242Lfs*15. |
cspec
vcep_mmc2
|
| PS4 | Not assessed | Not assessed: no variant-specific specificity score or qualifying case-control odds ratio, p value, and confidence interval are available for c.722_723dup. |
cspec
PMID:21194675
PMID:9467011
|
| PM1 | Not met | Not met: residue 242 is outside PTEN VCEP critical motifs 90-94, 123-130, and 166-168, and no E242 hotspot was identified. |
cspec
|
| PM2 | Met | Met at supporting: the variant is absent from gnomAD v2.1 and v4.1, satisfying the PTEN PM2 absence criterion below 0.00001 allele frequency. |
cspec
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: the PTEN VCEP explicitly designates PM3 as not applicable for this autosomal-dominant disorder. |
cspec
|
| PM4 | Not met | Not met: p.E242Lfs*15 is a frameshift with premature termination, whereas the PTEN PM4 rule requires an in-frame length change or stop-loss extension. |
cspec
|
| PM5 | N/A | Not applicable: c.722_723dup is a frameshift, while PTEN PM5 requires a different pathogenic missense change at the same residue. |
cspec
|
| PM6 | Not assessed | Not assessed: no documented presumed de novo proband observation, parental testing status, or family-history assessment for c.722_723dup. |
cspec
|
| PP1 | Not assessed | Not assessed: zero informative meioses or exact-variant affected-relative segregation data are documented, below the PTEN VCEP minimum of 3 meioses. |
cspec
|
| PP2 | N/A | Not applicable: PP2 is missense-specific, but c.722_723dup produces the frameshift p.(Glu242LeufsTer15). |
cspec
|
| PP3 | N/A | Not applicable: c.722_723dup is a frameshift variant, outside PP3's calibrated missense or intronic/splice-region computational scope. |
|
| PP4 | N/A | Not applicable: the PTEN Expert Panel framework incorporates phenotype specificity into PS4 and explicitly excludes independent PP4 use. |
cspec
|
| PP5 | N/A | Not applicable: PP5 is excluded by the PTEN framework, and ClinVar has no exact-variant expert-panel Pathogenic assertion. |
cspec
clinvar
|
| BA1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, rather than exceeding the PTEN BA1 threshold of 0.00056 allele frequency. |
cspec
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, below both PTEN BS1 intervals beginning at 0.0000043 allele frequency. |
cspec
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: no homozygous observation in a healthy or PHTS-unaffected individual is available to satisfy the PTEN BS2 rule. |
cspec
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no variant-specific benign functional result was found for the frameshift c.722_723dup / p.E242Lfs*15 in the governing PTEN assay material. |
cspec
vcep_mmc2
|
| BS4 | Not assessed | Not assessed: no tested affected relatives or family-level non-segregation observations are documented for c.722_723dup. |
cspec
|
| BP1 | N/A | Not applicable: the PTEN VCEP excludes BP1, and this variant is a frameshift rather than a missense change. |
cspec
|
| BP2 | Not assessed | Not assessed: no paired pathogenic PTEN variant or documented cis/trans/phase observation is available to satisfy the BP2 rule. |
cspec
|
| BP3 | N/A | Not applicable: the PTEN VCEP marks BP3 as unavailable, and p.E242Lfs*15 is a truncating frameshift rather than an in-frame repeat-region deletion. |
cspec
|
| BP4 | N/A | Not applicable: c.722_723dup is a frameshift variant, outside BP4's calibrated missense or intronic/splice-region computational scope. |
|
| BP5 | Not assessed | Not assessed: no two qualifying cases with a highly penetrant alternate diagnosis and non-overlapping PTEN histories are documented. |
cspec
oncokb
|
| BP6 | N/A | Not applicable: BP6 is excluded by the PTEN framework, and ClinVar has no exact-variant expert-panel Benign or Likely benign assertion. |
cspec
clinvar
|
| BP7 | N/A | Not applicable: c.722_723dup is a frameshift variant, not a synonymous variant eligible for BP7. |
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.